Search…

Lates News

30/03/2026

AstraZeneca (AZN.O) announced that the China National Medical Products Administration has officially approved the use of selumetinib capsules (trade name: Koselugo) for the treatment of type 1 neurofibromatosis (NF1) in children and adults aged 3 and above with symptomatic and inoperable plexiform neurofibromas (PN). This is currently the first and only drug approved for the treatment of this patient population aged 3 and above in China.

Latest

4 m ago

CITIC Securities has been approved to publicly issue corporate bonds to professional investors with a total amount not exceeding 60 billion yuan.

5 m ago

According to an announcement from iQiyi (IQ.O), the company has recently officially launched the public commercial testing of its independently developed AI intelligent assistant, Nadou Pro. Nadou Pro is the first domestic AI intelligent assistant designed specifically for professional long video production. It integrates leading basic models and iQiyi's deep experience in high-quality content production, effectively simplifying the entire production process from creative ideas to final video generation.

5 m ago

Teruite: The company is expected to win a total of about 184 million yuan in bids for projects.

6 m ago

The U.S. Treasury bond yield is dropping; the upcoming data or announcement is crucial to the outlook of the Federal Reserve.

6 m ago

More than 40 endangered species have been listed by the United Nations as protected migratory animals.

See all latest